Published in J Natl Cancer Inst on March 04, 1998
New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2013) 1.72
The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24
Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotechnol (2003) 1.11
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
A human embryonic kidney 293T cell line mutated at the Golgi alpha-mannosidase II locus. J Biol Chem (2009) 0.96
Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma. Cancer Res Treat (2005) 0.94
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (1999) 0.88
The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network. Biochem J (2008) 0.85
Eeyarestatin 1 interferes with both retrograde and anterograde intracellular trafficking pathways. PLoS One (2011) 0.85
Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clin Cancer Res (2010) 0.84
Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases. J Exp Clin Cancer Res (2015) 0.82
DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res (2013) 0.82
Gene- and viral-based therapies for brain tumors. Neurotherapeutics (2009) 0.81
Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells. World J Gastroenterol (2005) 0.79
A triple suicide gene strategy that improves therapeutic effects and incorporates multimodality molecular imaging for monitoring gene functions. Cancer Gene Ther (2013) 0.77
Gene-directed enzyme prodrug therapy. AAPS J (2014) 0.77
Re: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1999) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A (2000) 5.49
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science (1993) 5.05
The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci (2001) 4.33
Diagnostic criteria for schwannomatosis. Neurology (2005) 3.41
In vivo magnetic resonance imaging of transgene expression. Nat Med (2000) 3.35
Fos expression in orexin neurons varies with behavioral state. J Neurosci (2001) 3.08
Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem (1981) 3.01
Melanopsin in cells of origin of the retinohypothalamic tract. Nat Neurosci (2001) 2.79
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer (2009) 2.76
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother (1991) 2.66
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol (1976) 2.42
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem (1977) 2.32
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat Genet (1993) 2.23
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther (1998) 2.13
Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst (1999) 2.10
A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science (1988) 2.02
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol (2000) 1.94
Localization of human monoamine oxidase-A gene to Xp11.23-11.4 by in situ hybridization: implications for Norrie disease. Genomics (1989) 1.93
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc Natl Acad Sci U S A (2001) 1.90
Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet (2000) 1.90
Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif (2001) 1.86
Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses (1992) 1.85
Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol (1996) 1.82
Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc Natl Acad Sci U S A (2000) 1.81
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. Am J Hum Genet (1991) 1.77
Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem (1988) 1.77
Unusual electrocardiographic manifestation of pulmonary embolism. Am Heart J (1970) 1.74
Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther (1999) 1.69
Temperature-sensitive divisionless mutant of Bacillus subtilis defective in the initiation of septation. J Bacteriol (1973) 1.66
Contrasting effects of ibotenate lesions of the paraventricular nucleus and subparaventricular zone on sleep-wake cycle and temperature regulation. J Neurosci (2001) 1.62
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem (1991) 1.60
Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet (1991) 1.56
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A (1982) 1.53
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother (1986) 1.51
An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 1.46
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 1.45
Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther (2000) 1.45
Oncological management of pediatric cancer patients belonging to Jehovah's Witnesses: a two-institutional experience report. Onkologie (2004) 1.44
Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J Neurosurg (1993) 1.44
Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (1999) 1.44
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol (1999) 1.43
The binding of colchicine by sarcoma 180 cells. Biochem Pharmacol (1968) 1.43
A method of estimating curare-like activity on the isolated phrenic nerve diaphragm preparation of the rat. Br J Pharmacol Chemother (1947) 1.42
Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science (1988) 1.42
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives. J Med Chem (1993) 1.41
Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr (2000) 1.41
Are platelet cytosolic free calcium, serotonin concentration and blood viscosity different between hypertensive and normotensive subjects? Cardiology (1994) 1.40
Unexpected cardiac arrest in patients after surgical correction of tetralogy of Fallot. Circulation (1975) 1.40
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol (2000) 1.40
Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nat Genet (1993) 1.36
Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (1992) 1.36
Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol (1976) 1.35
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A (1999) 1.33
Structural gene for beta-nerve growth factor not defective in familial dysautonomia. Proc Natl Acad Sci U S A (1984) 1.32
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res (1999) 1.31
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta (1998) 1.31
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther (2006) 1.29
Biochemistry and genetics of monoamine oxidase. Pharmacol Ther (1990) 1.29
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol (2001) 1.28
Molecular imaging of gene therapy for cancer. Gene Ther (2004) 1.28
Unreliability of conventional electrocardiographic monitoring for arrhythmia detection in coronary care units. Am J Cardiol (1973) 1.28
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Isolation and characterization of a candidate gene for Norrie disease. Nat Genet (1992) 1.27
MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ (2009) 1.27
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol (1996) 1.27
Treatment of high-grade glioma in children and adolescents. Neuro Oncol (2011) 1.27
Rapid-onset dystonia-parkinsonism. Neurology (1993) 1.26
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses (1997) 1.26
Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis (1996) 1.26
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis (1990) 1.25
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother (1992) 1.25
Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol (1982) 1.24
Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol (1991) 1.22
Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J Comp Neurol (1994) 1.21
Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology (2002) 1.20
Dinucleotide repeat polymorphism (D16S285) on human chromosome 16. Nucleic Acids Res (1991) 1.20
Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol (1994) 1.19
Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics (2001) 1.18
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol (2001) 1.17
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res (1996) 1.17
Voltage-sensitive calcium channels regulate guanosine 3',5'-cyclic monophosphate levels in neuroblastoma cells. Proc Natl Acad Sci U S A (1978) 1.17